Clinical Study
Safety of Allogeneic Umbilical Cord Blood Stem Cells Therapy in Patients with Severe Cerebral Palsy: A Retrospective Study
Table 3
Frequency of adverse events after allogeneic UCBSCs treatment.
| | Type of adverse events | Number of reactions (%) | Time of occurrence (h) | Time of remission (h) |
| | Fever | 20 (42.6%) | 19.91 ± 21.76 | 28.62 ± 17.38 | | Vomiting | 10 (21.2%) | 12.00 ± 3.35 | 20.00 ± 6.20 | | Seizure | 3 (6.4%) | 19.50 ± 11.90 | 21.00 ± 6.00 | | Headache | 3 (6.4%) | 11.50 ± 7.78 | 36.00 ± 16.97 | | Upper respiratory tract infection | 2 (4.3%) | 38.50 ± 40.34 | 24.00 ± 0.00 | | Dermatitis | 2 (4.3%) | 12.50 ± 0.71 | 24.96 ± 13.34 | | Waist pain | 1 (2.1%) | 8.00 | 24.00 | | Constipation | 1 (2.1%) | 24.00 | 12.00 | | Diarrhea | 0 (0%) | — | — | | Insomnia | 0 (0%) | — | — | | Pneumonia | 0 (0%) | — | — | | Anorexia | 0 (0%) | — | — |
|
|
Note. UCBSCs: umbilical cord blood stem cells; h: hour.
|
